{"id":40744,"date":"2026-10-29T11:34:09","date_gmt":"2026-10-29T11:34:09","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=40744"},"modified":"2026-10-29T11:34:09","modified_gmt":"2026-10-29T11:34:09","slug":"hutchmed-wins-fda-orphan-drug-status-for-sovleplenib","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/","title":{"rendered":"HUTCHMED\u3001\u30bd\u30f4\u30ec\u30d7\u30ec\u30cb\u30d6\u306b\u3064\u3044\u3066FDA\u304b\u3089\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d6\u5f97\u3057\u305f"},"content":{"rendered":"

\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08FDA\uff09\u306f\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u307e\u305f\u306fITP\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3001\u30bd\u30f4\u30ec\u30d7\u30ec\u30cb\u30d6\u306b\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u4e0e\u3048\u305f\u3002HUTCHMED Limited\u306f2026\u5e7410\u670828\u65e5\u3001\u3053\u306e\u6c7a\u5b9a\u3092\u767a\u8868\u3057\u305f\u3002ITP\u306f\u3001\u8840\u5c0f\u677f\u6570\u304c\u6e1b\u5c11\u3057\u3066\u51fa\u8840\u306e\u30ea\u30b9\u30af\u304c\u9ad8\u307e\u308b\u75be\u60a3\u3067\u3042\u308b\u3002.<\/p>

\u30bd\u30f4\u30ec\u30d7\u30ec\u30cb\u30d6\u306f\u3001HUTCHMED\u304c\u958b\u767a\u4e2d\u306e\u533b\u85ac\u54c1\u3067\u3042\u308b\u3002\u3053\u308c\u306f\u3001\u813e\u81d3\u30c1\u30ed\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\uff08Syk\uff09\u306e\u7d4c\u53e3\u963b\u5bb3\u5264\u3067\u3042\u308b\u3002\u3053\u306e\u85ac\u306f1\u65e51\u56de\u306e\u670d\u7528\u3092\u60f3\u5b9a\u3057\u3066\u8a2d\u8a08\u3055\u308c\u3066\u3044\u308b\u3002\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u306f\u3001\u30bd\u30f4\u30ec\u30d7\u30ec\u30cb\u30d6\u306e\u958b\u767a\u306b\u304a\u3051\u308b\u91cd\u8981\u306a\u7bc0\u76ee\u3067\u3042\u308b\u3002.<\/p>

The FDA’s Orphan Drug Designation program helps promote the development of medicines for diseases. These are conditions affecting than 200,000 people in the United States. The designation does not mean the drug is approved for use. It does not mean the drug is safe or effective for the public.. It does offer benefits to companies that are developing drugs for rare diseases.<\/p>

\u30bd\u30f4\u30ec\u30d7\u30ec\u30cb\u30d6\u306e\u5834\u5408\u3001\u3053\u308c\u3089\u306e\u30e1\u30ea\u30c3\u30c8\u306b\u306f\u3001\u6307\u5b9a\u3055\u308c\u305f\u9069\u5fdc\u75c7\u306b\u3064\u3044\u3066\u627f\u8a8d\u3055\u308c\u305f\u5834\u5408\u306b\u3001\u7c73\u56fd\u30677\u5e74\u9593\u306e\u5e02\u5834\u72ec\u5360\u6a29\u304c\u5f97\u3089\u308c\u308b\u3053\u3068\u304c\u542b\u307e\u308c\u308b\u3002\u307e\u305f\u3001\u4e00\u5b9a\u306e\u57fa\u6e96\u3092\u6e80\u305f\u3059\u81e8\u5e8a\u8a66\u9a13\u306b\u5bfe\u3059\u308b\u7a0e\u984d\u63a7\u9664\u3082\u542b\u307e\u308c\u308b\u3002\u3055\u3089\u306b\u3001\u533b\u85ac\u54c1\u958b\u767a\u4f01\u696d\u306f\u3001FDA\u306e\u4f7f\u7528\u6599\u306e\u4e00\u90e8\u306b\u3064\u3044\u3066\u514d\u9664\u3092\u53d7\u3051\u308b\u53ef\u80fd\u6027\u3082\u3042\u308b\u3002\u958b\u767a\u671f\u9593\u4e2d\u306f\u3001FDA\u304b\u3089\u306e\u5c02\u9580\u7684\u306a\u6307\u5c0e\u3092\u53d7\u3051\u308b\u3053\u3068\u304c\u3067\u304d\u308b\u3002.<\/p>

\u539f\u767a\u6027\u514d\u75ab\u6027\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u306e\u7406\u89e3<\/h3>

ITP\u306f\u3001\u514d\u75ab\u7cfb\u304c\u8840\u5c0f\u677f\u3092\u653b\u6483\u3057\u3066\u7834\u58ca\u3057\u3001\u3055\u3089\u306b\u8840\u5c0f\u677f\u306e\u751f\u6210\u3082\u6b62\u3081\u3066\u3057\u307e\u3046\u3053\u3068\u3067\u767a\u75c7\u3059\u308b\u3002\u8840\u5c0f\u677f\u306f\u8840\u6db2\u51dd\u56fa\u306b\u4e0d\u53ef\u6b20\u3067\u3042\u308b\u305f\u3081\u3001ITP\u306e\u60a3\u8005\u306f\u3042\u3056\u304b\u3089\u5927\u91cf\u306b\u51fa\u8840\u3057\u305f\u308a\u3001\u305d\u306e\u4ed6\u306e\u554f\u984c\u306b\u60a9\u307e\u3055\u308c\u305f\u308a\u3059\u308b\u3053\u3068\u304c\u3042\u308b\u3002ITP\u306f\u75b2\u52b4\u611f\u3092\u5f15\u304d\u8d77\u3053\u3059\u3053\u3068\u3082\u3042\u308b\u3002ITP\u306f\u751f\u6d3b\u306e\u8cea\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u3002\u79c1\u306f\u3001ITP\u306b\u3088\u3063\u3066\u65e5\u5e38\u306e\u4f5c\u696d\u304c\u3069\u308c\u307b\u3069\u56f0\u96e3\u306b\u306a\u308b\u304b\u3092\u76ee\u306e\u5f53\u305f\u308a\u306b\u3057\u3066\u304d\u305f\u3002.<\/p>

ITP\u306f\u60a3\u8005\u306b\u3088\u3063\u3066\u75c7\u72b6\u306b\u5927\u304d\u306a\u3070\u3089\u3064\u304d\u304c\u3042\u308b\u3002\u65e2\u5b58\u306eITP\u6cbb\u7642\u306b\u53cd\u5fdc\u3059\u308b\u60a3\u8005\u304c\u3044\u308b\u4e00\u65b9\u3067\u3001\u75c5\u72b6\u304c\u60aa\u5316\u3057\u305f\u308a\u3001\u518d\u767a\u3057\u305f\u308a\u3001\u3042\u308b\u3044\u306f\u5229\u7528\u53ef\u80fd\u306a\u6cbb\u7642\u6cd5\u3078\u306e\u53cd\u5fdc\u304c\u9650\u5b9a\u7684\u3060\u3063\u305f\u308a\u3059\u308b\u60a3\u8005\u3082\u3044\u308b\u3002\u3053\u306e\u305f\u3081\u3001\u7570\u306a\u308b\u4f5c\u7528\u6a5f\u5e8f\u3092\u6301\u3064ITP\u306e\u6cbb\u7642\u6cd5\u304c\u5fc5\u8981\u3068\u3055\u308c\u3066\u3044\u308b\u3002\u79c1\u306f\u3001\u6cbb\u7642\u3092\u8a66\u3057\u7d9a\u3051\u3066\u3044\u308b\u60a3\u8005\u3092\u6570\u591a\u304f\u898b\u3066\u304d\u305f\u3002.<\/p>

HUTCHMED\u793e\u306b\u3088\u308b\u3068\u3001ITP\u306e\u63a8\u5b9a\u767a\u75c7\u7387\u306f\u6210\u4eba10\u4e07\u4eba\u3042\u305f\u308a3.3\u4f8b\u3001\u6709\u75c5\u7387\u306f\u6210\u4eba10\u4e07\u4eba\u3042\u305f\u308a9.5\u4f8b\u3067\u3042\u308b\u3002 \u3053\u308c\u3089\u306e\u63a8\u8a08\u306b\u57fa\u3065\u304f\u3068\u3001\u7c73\u56fd\u3001\u30c9\u30a4\u30c4\u3001\u30d5\u30e9\u30f3\u30b9\u3001\u30a4\u30bf\u30ea\u30a2\u3001\u30b9\u30da\u30a4\u30f3\u3001\u82f1\u56fd\u3001\u65e5\u672c\u306b\u306f5\u4e076,000\u4eba\u306eITP\u60a3\u8005\u304c\u304a\u308a\u3001\u3055\u3089\u306b\u4e2d\u56fd\u306b\u306f\u63a8\u8a0811\u4e07\u4eba\u306e\u60a3\u8005\u304c\u3044\u308b\u3002\u3053\u308c\u3089\u306e\u6570\u5b57\u306f\u3001\u591a\u304f\u306e\u5bb6\u65cf\u304c\u5f71\u97ff\u3092\u53d7\u3051\u3066\u3044\u308b\u3053\u3068\u3092\u610f\u5473\u3059\u308b\u3068\u805e\u3044\u3066\u3044\u308b\u3002.<\/p>

\u3053\u308c\u3089\u306e\u6570\u5024\u306f\u3001ITP\u306e\u4e3b\u8981\u306a\u533b\u85ac\u54c1\u5e02\u5834\u306b\u304a\u3044\u3066\u3001\u65b0\u3057\u3044\u6cbb\u7642\u6cd5\u304c\u3044\u304b\u306b\u91cd\u8981\u3067\u3042\u308b\u304b\u3092\u6d6e\u304d\u5f6b\u308a\u306b\u3057\u3066\u3044\u308b\u3002\u3057\u304b\u3057\u3001ITP\u306e\u627f\u8a8d\u6e08\u307f\u533b\u85ac\u54c1\u306e\u9069\u7528\u5bfe\u8c61\u3068\u306a\u308b\u6700\u7d42\u7684\u306a\u60a3\u8005\u96c6\u56e3\u306f\u3001\u305d\u306e\u627f\u8a8d\u3055\u308c\u305f\u9069\u5fdc\u75c7\u3001\u81e8\u5e8a\u7684\u30a8\u30d3\u30c7\u30f3\u30b9\u3001\u304a\u3088\u3073\u73fe\u5730\u306e\u6cbb\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u306b\u3088\u3063\u3066\u6c7a\u307e\u308b\u3053\u3068\u306b\u306a\u308b\u3002\u79c1\u306f\u3001\u60a3\u8005\u4e00\u4eba\u3072\u3068\u308a\u306b\u5408\u308f\u305b\u305f\u6cbb\u7642\u3092\u884c\u3046\u3053\u3068\u304c\u4e0d\u53ef\u6b20\u3060\u3068\u8003\u3048\u3066\u3044\u308b\u3002.<\/p>

Sovleplenib’s Development and Regulatory Position<\/h3>

\u30bd\u30f4\u30ec\u30d7\u30ec\u30cb\u30d6\u306f\u3001\u7d30\u80de\u5185\u3067\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3092\u52a9\u3051\u308b\u30bf\u30f3\u30d1\u30af\u8cea\u3067\u3042\u308bSyk\u3092\u6a19\u7684\u3068\u3059\u308b\u3002ITP\u3067\u306f\u3001Syk\u306b\u3088\u308b\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u304c\u514d\u75ab\u7cfb\u306b\u3088\u308b\u8840\u5c0f\u677f\u306e\u7834\u58ca\u3092\u52a9\u9577\u3059\u308b\u3002\u7814\u7a76\u8005\u305f\u3061\u306f\u3001\u30bd\u30f4\u30ec\u30d7\u30ec\u30cb\u30d6\u3092\u7528\u3044\u3066\u3053\u306e\u7d4c\u8def\u3092\u963b\u5bb3\u3059\u308b\u3053\u3068\u304c\u3001ITP\u306e\u7ba1\u7406\u306b\u3069\u306e\u3088\u3046\u306b\u5f79\u7acb\u3064\u304b\u306b\u3064\u3044\u3066\u7814\u7a76\u3092\u9032\u3081\u3066\u3044\u308b\u3002.<\/p>

HUTCHMED said that applications for Sovleplenib to treat ITP and warm antibody autoimmune hemolytic anemia are being reviewed by China’s National Medical Products Administration. Those applications rely on data from the company’s trials, ESLIM-01 and ESLIM-02.<\/p>

The company keeps rights to Sovleplenib. The FDA has given Sovleplenib a rare‑disease label, which offers some incentives in the United States. Still clinical work and regulatory approvals are needed before Sovleplenib could be sold for ITP, in the United States.<\/p>

\u3053\u306e\u9055\u3044\u306f\u3001\u6295\u8cc7\u5bb6\u3001\u533b\u5e2b\u3001\u305d\u3057\u3066\u60a3\u8005\u306b\u3068\u3063\u3066\u91cd\u8981\u3060\u3002\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u306f\u3001\u958b\u767a\u3092\u5f8c\u62bc\u3057\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002\u305f\u3060\u3057\u3001\u627f\u8a8d\u3084\u5e02\u5834\u3067\u306e\u6210\u529f\u3001\u3042\u308b\u3044\u306f\u7279\u5b9a\u306e\u6cbb\u7642\u6210\u679c\u3092\u4fdd\u8a3c\u3059\u308b\u3082\u306e\u3067\u306f\u306a\u3044\u3002.<\/p>

\u65e5\u672c\u306e\u88fd\u85ac\u696d\u754c\u3078\u306e\u5f71\u97ff<\/h3>

The announcement also has implications for Japan’s pharmaceutical and biotechnology sector. Although the FDA decision applies to the US system the underlying development strategy is relevant to companies working on rare diseases and specialized treatments.<\/p>

I see that Japan has an established pharmaceutical market and many patients suffer from ITP. I believe that new treatments which show benefits for people with persistent disease could eventually widen the choices available for patients provided the treatments have strong clinical evidence and receive approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).<\/p>

For me this case shows how vital it is for pharmaceutical companies to develop medications for defined patient groups and to follow regulatory plans that cover many markets. I also think that orphan‑drug incentives can lower some development costs and give advantages but research, into diseases remains uncertain both scientifically and financially.<\/p>

The announcement also illustrates the role of regulatory pathways in pharmaceutical development. A designation in one market may support a company’s development plans but it does not automatically transfer to another jurisdiction. Any future availability of sovleplenib, in Japan would depend on the Japanese regulatory process and the evidence submitted to authorities.<\/p>

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a \u30ea\u30ba\u30e0\u30fb\u30d5\u30a1\u30fc\u30de\u30b7\u30e5\u30fc\u30c6\u30a3\u30ab\u30eb\u30ba\u3001\u8996\u5e8a\u4e0b\u90e8\u6027\u80a5\u6e80\u6cbb\u7642\u85ac\u300cIM CIVREE\u300d\u3092\u65e5\u672c\u3067\u767a\u58f2\u3057\u305f<\/a><\/h4>

\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u306b\u3068\u3063\u3066\u3001\u7279\u5b9a\u306e\u75be\u60a3\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u3001\u672a\u5145\u8db3\u306e\u533b\u7642\u30cb\u30fc\u30ba\u306b\u5fdc\u3048\u3001\u72ec\u81ea\u306e\u533b\u85ac\u54c1\u30dd\u30fc\u30c8\u30d5\u30a9\u30ea\u30aa\u3092\u62e1\u5927\u3059\u308b\u6a5f\u4f1a\u3092\u3082\u305f\u3089\u3059\u3002\u898f\u5236\u4e0a\u306e\u512a\u9047\u63aa\u7f6e\u306b\u3088\u308a\u3001\u958b\u767a\u30b3\u30b9\u30c8\u3092\u524a\u6e1b\u3067\u304d\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002\u3068\u306f\u3044\u3048\u3001\u4f01\u696d\u306f\u4f9d\u7136\u3068\u3057\u3066\u3001\u533b\u85ac\u54c1\u306e\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u3092\u793a\u3059\u81e8\u5e8a\u8a66\u9a13\u306e\u8cbb\u7528\u3092\u8ca0\u62c5\u3057\u3001\u88fd\u9020\u30fb\u8ca9\u58f2\u306b\u5411\u3051\u305f\u6e96\u5099\u3092\u6574\u3048\u306a\u3051\u308c\u3070\u306a\u3089\u306a\u3044\u3002.<\/p>

\u533b\u7642\u5f93\u4e8b\u8005\u306b\u3068\u3063\u3066\u3001\u30bd\u30f4\u30ec\u30d7\u30ec\u30cb\u30d6\u304c\u3069\u308c\u307b\u3069\u6709\u7528\u3067\u3042\u308b\u304b\u306f\u3001\u5c06\u6765\u7684\u306a\u30a8\u30d3\u30c7\u30f3\u30b9\u306b\u3088\u3063\u3066\u3001\u73fe\u5728\u306e\u9078\u629e\u80a2\u3068\u6bd4\u8f03\u3057\u3066\u5229\u76ca\u3068\u30ea\u30b9\u30af\u306e\u30d0\u30e9\u30f3\u30b9\u304c\u53d6\u308c\u3066\u3044\u308b\u304b\u3069\u3046\u304b\u304c\u793a\u3055\u308c\u308b\u304b\u3069\u3046\u304b\u306b\u304b\u304b\u3063\u3066\u3044\u308b\u3002\u60a3\u8005\u306f\u3001\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u8868\u793a\u304c\u3042\u308b\u304b\u3089\u3068\u3044\u3063\u3066\u5b9f\u9a13\u7684\u306a\u85ac\u5264\u3092\u4f7f\u7528\u3059\u3079\u304d\u3060\u3068\u8003\u3048\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u6cbb\u7642\u6cd5\u306e\u9078\u629e\u306b\u3064\u3044\u3066\u306f\u5f15\u304d\u7d9a\u304d\u533b\u5e2b\u3092\u4fe1\u983c\u3059\u3079\u304d\u3060\u3002.<\/p>

HUTCHMED’s announcement shows progress in sovleplenib’s work for ITP. The next key steps are clinical tests and regulatory moves such as seeing if sovleplenib can prove enough evidence to get approval, in the United States or other places.<\/p>

 <\/p>","protected":false},"excerpt":{"rendered":"

The US Food and Drug Administration has given Orphan Drug Designation to sovleplenib, for treatment of thrombocytopenia or ITP. HUTCHMED Limited announced this decision on October 28 2026. ITP is a condition that causes platelet counts and increases the risk of bleeding.Sovleplenib is a drug being developed by HUTCHMED. It is an oral inhibitor of spleen tyrosine kinase or Syk. The drug is designed to be taken a day. The Orphan Drug Designation is a milestone in the development of sovleplenib.The FDA’s Orphan Drug Designation program helps promote the development of medicines for diseases. These are conditions affecting than 200,000 people in the United States. The designation does not mean […]<\/p>\n","protected":false},"author":7,"featured_media":40769,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,8098,182],"tags":[16604,14505,16605,346,575],"ppma_author":[572],"class_list":["post-40744","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-tech","category-news-articles","category-pharma","tag-drug-designation","tag-fda","tag-hutchmed","tag-manufacturing","tag-pharmaceutical"],"yoast_head":"\nHUTCHMED Announces FDA Designation for Sovleplenib<\/title>\n<meta name=\"description\" content=\"HUTCHMED announces that sovleplenib has received US FDA orphan drug designation for primary immune thrombocytopenia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HUTCHMED Announces FDA Designation for Sovleplenib\" \/>\n<meta property=\"og:description\" content=\"HUTCHMED announces that sovleplenib has received US FDA orphan drug designation for primary immune thrombocytopenia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-29T11:34:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/10\/HUTCHMED-Announces-Sovleplenib-Granted-US-FDA-Orphan-Drug-Designation-for-Primary-Immune-Thrombocytopenia.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HUTCHMED Announces FDA Designation for Sovleplenib","description":"HUTCHMED announces that sovleplenib has received US FDA orphan drug designation for primary immune thrombocytopenia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/","og_locale":"ja_JP","og_type":"article","og_title":"HUTCHMED Announces FDA Designation for Sovleplenib","og_description":"HUTCHMED announces that sovleplenib has received US FDA orphan drug designation for primary immune thrombocytopenia.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/","og_site_name":"itbusinesstoday","article_published_time":"2026-10-29T11:34:09+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/10\/HUTCHMED-Announces-Sovleplenib-Granted-US-FDA-Orphan-Drug-Designation-for-Primary-Immune-Thrombocytopenia.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"5\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"HUTCHMED Wins FDA Orphan Drug Status for Sovleplenib","datePublished":"2026-10-29T11:34:09+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/"},"wordCount":914,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/10\/HUTCHMED-Announces-Sovleplenib-Granted-US-FDA-Orphan-Drug-Designation-for-Primary-Immune-Thrombocytopenia.webp","keywords":["Drug Designation","FDA","HUTCHMED","Manufacturing","pharmaceutical"],"articleSection":["Health Tech","News Articles","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/","name":"HUTCHMED Announces FDA Designation for Sovleplenib","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/10\/HUTCHMED-Announces-Sovleplenib-Granted-US-FDA-Orphan-Drug-Designation-for-Primary-Immune-Thrombocytopenia.webp","datePublished":"2026-10-29T11:34:09+00:00","description":"HUTCHMED announces that sovleplenib has received US FDA orphan drug designation for primary immune thrombocytopenia.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/10\/HUTCHMED-Announces-Sovleplenib-Granted-US-FDA-Orphan-Drug-Designation-for-Primary-Immune-Thrombocytopenia.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/10\/HUTCHMED-Announces-Sovleplenib-Granted-US-FDA-Orphan-Drug-Designation-for-Primary-Immune-Thrombocytopenia.webp","width":1200,"height":800,"caption":"HUTCHMED"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/hutchmed-wins-fda-orphan-drug-status-for-sovleplenib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"HUTCHMED Wins FDA Orphan Drug Status for Sovleplenib"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"author_category":"","first_name":"ITBT","last_name":"StaffWriter","user_url":"https:\/\/itbusinesstoday.com\/","job_title":"","description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002"}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/40744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=40744"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/40744\/revisions"}],"predecessor-version":[{"id":40745,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/40744\/revisions\/40745"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/40769"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=40744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=40744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=40744"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=40744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}